Company: TAK
Filing Date: 2025-01-30
Form Type: 6-K
Source: 0001395064-25-000002
Chunk: 1

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-01-30
Form: 6-K
Chunk 1
---
  9.0 |     |                 507 |     |       |     |                                                  |     |       |     |                |

(Note) Modifications in forecasts of consolidated operating results from the latest announcement: Yes

The definition of Core financial measures is stated in “Definition and Explanation of Non-IFRS Measures and U.S. Dollar Convenience Translations” in the Financial Appendix.

Takeda uses change in Core Revenue, Core Operating Profit and Core EPS at Constant Exchange Rate (CER) basis as its Management Guidance. The full year management guidance for the fiscal year ending March 31, 2025 (FY2024) has been revised from the previous management guidance announced on October 31, 2024, as follows:

The definition of Constant Exchange Rate change is stated in “Definition and Explanation of Non-IFRS Measures and U.S. Dollar Convenience Translations” in the Financial Appendix.

#### ▪

#### Additional Information
| (1) Significant changes in the scope of consolidation during the period                |     | : No |     |                      |
| (2) Changes in accounting policies and changes in accounting estimates                 |     |      |     |                      |
| 1) Changes in accounting policies required by IFRS                                     |     | : No |     |                      |
| 2) Changes in accounting policies other than 1)                                        |     | : No |     |                      |
| 3) Changes in accounting estimates                                                     |     | : No |     |                      |
| (3) Number of shares outstanding (common stock)                                        |     |      |     |                      |
| 1) Number of shares outstanding (including treasury stock) at period end:              |     |      |     |                      |
| December 31, 2024                                                                      |     |      |     | 1,590,937,609 shares |
| March 31, 2024                                                                         |     |      |     | 1,582,418,725 shares |
| 2) Number of shares of treasury stock at period end:                                   |     |      |     |                      |
| December 31, 2024                                                                      |     |      |     | 5,758,360 shares     |
| March 31, 2024                                                                         |     |      |     | 13,405,261 shares    |
| 3) Average number of outstanding shares (for the nine-month period ended December 31): |     |      |     |                      |
| December